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Abstract
Autosomal Dominant Optic Atrophy (ADOA) is the most common inherited optic atrophy where vision impairment results
from specific loss of retinal ganglion cells of the optic nerve. Around 60% of ADOA cases are linked to mutations in the OPA1
gene. OPA1 is a fission-fusion protein involved in mitochondrial inner membrane remodelling. ADOA presents with marked
variation in clinical phenotype and varying degrees of vision loss, even among siblings carrying identical mutations in OPA1.
To determine whether the degree of vision loss is associated with the level of mitochondrial impairment, we examined
mitochondrial function in lymphoblast cell lines obtained from six large Australian OPA1-linked ADOA pedigrees.
Comparing patients with severe vision loss (visual acuity [VA],6/36) and patients with relatively preserved vision (VA.6/9)
a clear defect in mitochondrial ATP synthesis and reduced respiration rates were observed in patients with poor vision. In
addition, oxidative phosphorylation (OXPHOS) enzymology in ADOA patients with normal vision revealed increased complex
II+III activity and levels of complex IV protein. These data suggest that OPA1 deficiency impairs OXPHOS efficiency, but
compensation through increases in the distal complexes of the respiratory chain may preserve mitochondrial ATP
production in patients who maintain normal vision. Identification of genetic variants that enable this response may provide
novel therapeutic insights into OXPHOS compensation for preventing vision loss in optic neuropathies.
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Introduction
Autosomal Dominant Optic Atrophy (ADOA, OMIM 165500),
also known as Kjer’s optic neuropathy [1] is the most common
hereditary optic neuropathy with a prevalence at 1:12000 [2].
ADOA leads to vision impairment due to the degeneration of
retinal ganglion cells (RGCs) and their axons in the optic nerve
[3,4,5]. The ADOA phenotype and degree of vision loss often
varies considerably within a given pedigree, with a spectrum of
vision loss ranging from mild to severe [6,7]. The optic neuropathy
often manifests in early childhood with reduced visual acuity, a
predominantly blue-yellow dyschromatopsia and central scotoma
(blind spot) [8,9].
Over 60% of ADOA has been linked to mutations in the
nuclear-encoded mitochondrial protein OPA1, with over 220
mutations identified to date [7,10,11,12]. The OPA1 protein plays
an important role in regulating mitochondrial inner membrane
fusion [13,14,15,16] and blocking the release of cytochrome c to
prevent apoptosis [15]. A number of studies have demonstrated
the role of OPA1 in maintaining an intact mitochondrial network
through promoting mitochondrial fusion. This network allows the
cell to rapidly respond to changing metabolic needs by adjusting
mitochondrial distribution [17] and ensures adequate ‘‘mixing’’ of
mitochondrial proteins and mitochondrial DNA (mtDNA).
However it is becoming increasingly apparent that OPA1 also
has a direct role in modulating cellular bioenergetic status. OPA1
has been shown to interact directly with OXPHOS complexes I, II
and III but not IV [18]. Furthermore evidence of OXPHOS
dysfunction and defective ATP production in OPA1 animal
models [19,20,21,22,23,24] and skeletal muscle from ADOA
patients is accumulating [18,25,26].
The considerable inter- and intra-familial variation in visual acuity
and penetrance within OPA1 pedigrees [1,6,27,28,29,30,31] has
largelybeen ignored in priorstudies of OXPHOS function in ADOA
patient cohorts. These variations in phenotypes imply that aside from
OPA1 mutations there may be other genetic, epigenetic and/or
environmental modifiers influencing disease progression. The
mitochondrial haplogroup has been excluded as a disease modifier
in ADOA [32,33]. There is currently no known cure or treatment for
ADOA, and given the central role played by mitochondrial
dysfunction in ADOA, mechanistic studies on mitochondrial function
may reveal disease pathways amenable to therapeutic intervention.
Prior studies in LHON have demonstrated OXPHOS deficien-
cy in lymphoblast mitochondria [34,35]. We used a similar
technique to demonstrate clear differences in OXPHOS function
in lymphoblast mitochondria derived from a large cohort of
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lymphoblast mitochondria from ADOA patients with normal vision
had increased respiration rates and increased complex II+III (linked)
activity and complex IV protein levels compared to ADOA patients
with poor vision. Further, the level of ATP synthesis in mitochondria
of ADOA patients with near normal vision was similar to that of non-
mutation carriers, but significantly higher than for ADOA patients
with poor vision. These findings indicate that aspects of mitochon-
drial function segregate with visual acuity in ADOA patients, and
point to potential therapeutic targets for preserving vision in this
mitochondrial optic neuropathy.
Results
Pedigree and patient characteristics
ADOA is characterised by varying degrees of vision loss in
siblings with identical mutations in OPA1. An example family
pedigree (Figure 1A) shows the clinical severity of ADOA in family
members with the same exon27 4bpdel 2708delTTAG OPA1
mutation. The fundus photos from one sibship in the exon27
4bpdel 2708delTTAG pedigree illustrates the highly variable
clinical findings between four siblings and parent-offspring
(Figure 1B); the two siblings on the left with poor vision show
thinning and pallor of the neuroretinal rim of the optic nerve head
whilst the two siblings with near-normal vision have normal optic
disc appearances. Visual acuities for each eye are shown below the
photographs. There is a broad range of visual acuities observed
within each pedigree as well as in the combined pedigrees
(Figure 2A).
To identify potential mechanisms underlying the cause of vision
loss in ADOA we sampled patients from six large Australian OPA-
1 linked ADOA pedigrees. There are more than 220 known OPA1
mutations [12], and in this study each of these six pedigrees
represented a different OPA1 mutation or substitution. We
sampled patients from families that contained individuals in the
highest and lowest tertile for visual acuity (Figure 2A). This
selection included patients with either very poor vision (visual
acuity 6/36 or less, n=8) or with relatively normal vision (VA 6/9
or greater, n=7). Across the six pedigrees there were a total of 158
patients carrying OPA1 mutations which have been extensively
described [6,7].
To select patients according to differing visual acuity levels, we
selected families where siblings within the same family had a wide
range of VA. This variation is well described in prior studies
[1,6,27,28,29,30,31] and does not differ significantly according to
the OPA1 mutation [6,27]. Thus we believed that pooling of
patients from different pedigrees containing various OPA1
mutations was justified as a means to examine biochemical
changes associated with vision loss. Selected patients had stable
vision. We have recently reported that overall within the wider
cohort, visual acuities were stable in the majority of patients (72%)
over a 10-year (average) follow-up period [6]. Other investigators
have reported a gradual decline of vision (0.032+/0.045 logMAR/
year) [27], but this was not evident in the majority (72%) of our
cohort [6]. ADOA has been reported to manifest during
childhood, often as early as 3–5 years of age, and in a recent
study 80% of individuals were symptomatic before the age of 10
years, with the average age of onset being 7 years [27].
Considering all pedigrees, the mean age at examination was 38
years (620 years). In this cohort the average age of onset of vision
impairment was 10.2+/210.1 years [7]. Across the whole study
population there was no statistical difference between the initial
visual acuity measurement and visual acuity measured at a follow-
up visit an average of 9.6+/27.9 years later [6]. Furthermore
there were no significant differences in the rate of visual loss
between families harbouring different OPA1 mutations [6]. Thus
age of onset, OPA1 mutation and time since diagnosis are not
thought to be confounding factors and there was no significant
difference in the mean age between groups.
OPA1 expression, mitochondrial DNA content and
mitochondrial structure in ADOA cells
OPA1 haploinsufficiency is a consequence of most ADOA-
associated OPA1 mutations [7,36]. To determine if our lympho-
blast cellular model expressed OPA1 haploinsufficiency, total
protein lysates from cell lines from ADOA patients and controls
were examined for expression levels of OPA1 by western blotting
(Figure 3B). We detected two major bands corresponding to OPA1
just above and below 90 kDa (Figure 3A), corresponding to the
92 kDa and 86 kDa isoforms previously reported by other groups
[37]. Normalisation of total OPA1 content to actin showed a
significant reduction in total OPA1 content by around 60% in
patients with ADOA (p,0.001), with no difference in levels
between patients with poor vision and normal vision (Figure 3).
This confirms that OPA1 mutations result in equal levels of
haploinsufficiency of OPA1 in our lymphoblast cell lines between
patients with normal or poor visual acuity. We also found no
difference in the processing of OPA1 isoforms between groups
(data not shown). Function of the OPA1 protein appears to be
modified by alternative splicing events which regulate mitochon-
drial morphology [12,38,39,40].
OPA1 may preserve mtDNA stability, because in yeast models
lacking a homologue of OPA1 [41] or in more severe cases of
ADOA [25,42] multiple deletions and depletions of mtDNA have
been identified [42]. To explore possible changes in mtDNA
quantity, or the presence of large mtDNA deletions in patient
lymphoblasts, we visualized mtDNA by southern blotting. We did
not observe any large-scale deletions in mtDNA, which would be
detected as smaller fragments appearing on the southern blot
(Figure S1A). There was also no significant difference in the
mtDNA copy number between ADOA groups or controls (Figure
S1B). The mean ratio of mtDNA/18SRNA probe signal in control
patients (n=10) was 2.91+/20.49 (+/2 SEM), 2.46+/20.29 in
ADOA patients with normal vision (n=7) and 2.55+/20.35 in
ADOA patients with poor vision (n=8).
Because OPA1 plays a key role in mitochondrial fission/fusion,
we assessed whether OPA1 haploinsufficiency in the normal vision
and poor vision ADOA cells induced structural changes to the
mitochondria, or affected the mitochondrial density per cell. To
investigate this we quantified mitochondrial area per cell by
transmission electron microscopy (Figure S2). There was no
significant difference in mitochondrial area per cell (2 way
ANOVA, P.0.05) between any of the groups (Figure S2) nor
were there any changes in the size distribution of individual
mitochondria between groups (Figure S2). Thus in this cellular
model we observe OPA1 haploinsufficiency characteristic of
ADOA, without depletion of mitochondrial DNA or gross
disruption of mitochondrial volume or structure.
Impaired ATP synthesis in ADOA patients with poor
vision
We hypothesised that ADOA patients with poor vision would
demonstrate an impairment in mitochondrial energy production.
To investigate mitochondrial energy production in ADOA cells we
measured the rate of mitochondrial ATP synthesis in digitonin
permeabilised cells provided with complex I substrates (glutamate
+ malate) or complex II substrate (succinate + rotenone) in the
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complex I (Figure 4A) and complex II driven ATP synthesis rates
(Figure 4B) in poor vision ADOA patients compared to controls.
The rates of complex I driven ATP synthesis in poor vision ADOA
patients were decreased to 49% of controls (p,0.05), and the
complex II driven ATP synthesis rate was 57% of controls
(p,0.05). Normal vision patient cells in contrast did not show
significantly lower ATP production rates.
We also investigated whether this defect in ATP synthesis
correlated with impaired mitochondrial oxygen consumption,
which provides an indirect measurement of overall electron
transport chain activity via endogenous mitochondrial respiration.
Measurement of the endogenous respiration state in intact cells
revealed a small but significant increase in the respiration rate of
normal vision ADOA cells compared to poor vision ADOA cells
and controls (Figure 4C). Together with the relative preservation
of ATP production rate in normal vision patients, this suggests that
this normal vision patient group is able to better upregulate
respiration to partially compensate an ATP production deficit due
to OPA1 haploinsufficiency.
Increased oxidative phosphorylation enzyme activity
associated with normal vision ADOA
A detailed OXPHOS enzymology study was undertaken to
investigate whether modulation of this pathway may correlate with
the observed increase in normal vision patient cell respiration and
Figure 1. ADOA pedigree. A) A portion of the largest of the three pedigrees used in this study where patients are carrying the exon27 4bpdel
2708delTTAG OPA1 mutation. Black squares and circles indicate clinically affected, and white squares and circles indicate clinically unaffected
members. The circled members were included in this study. B) An example of variation in fundus findings within a sibship is shown. Fundus photos
from one sibship in the exon27 4bpdel 2708delTTAG OPA1 pedigree illustrate the highly variable clinical findings, showing thinning and pallor of the
neuroretinal rim of the optic disc in the two patients at left compared with the two patients at right. Visual acuities are shown for each eye below the
photographs. Variation in visual acuity was observed between siblings and parent-offspring.
doi:10.1371/journal.pone.0021347.g001
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OXPHOS enzyme complexes I, II, II+III, III, IV and the Kreb’s
cycle enzyme citrate synthase (CS) were measured in mitochon-
drial fractions from patient cells.
The specific activity of OXPHOS complexes II+III, (a linked
assay that relies on endogenous ubiquinone) was significantly
increased in normal vision patient mitochondria compared with
controls (Figure 5A). Similar trends (not reaching statistical
Figure 2. ADOA patient characteristics. A) Distribution of visual acuities (horizontal black bars) with mean visual acuity (white) per pedigree, and
total visual acuity spread, and sampled patients (black) in our population. B) Map of the OPA1 gene and localisation of the mutations analysed in this
study.
doi:10.1371/journal.pone.0021347.g002
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trend was not seen for complexes I or II (Figure 5D, E). This
indicates that the higher endogenous respiration in normal vision
ADOA may be accounted for by an increase in the specific activity
of certain OXPHOS enzymes.
Increased mitochondrial protein expression in normal
vision ADOA cells
To further explore the changes observed in OXPHOS complex
activities levels of OXPHOS proteins were visualized by western
blotting (Figure 6A). The levels of two complex IV subunits, both
nuclear and mitochondrial DNA encoded, were significantly
increased in normal vision ADOA compared to poor vision
ADOA and controls (Figure 6A and B, P,0.05). In normal vision
ADOA the expression levels of the nuclear encoded CxIV subunit
(Va) was increased to 145% and the mitochondrial encoded CxIV
subunit (II) to 139% of poor vision ADOA patient cells. We also
recorded a 145% increase in the expression of porin in patients
with normal vision (p,0.01), compared to poor vision and controls
(Figure 6C). No differences were seen among the groups for
subunits of complex I, II or III (data not shown).
Gene expression levels by RT-PCR and western blotting
We explored the mechanism of the increase in OXPHOS
function by measuring expression levels of key proteins in the
mitochondrial biogenesis pathway. In particular we measured
both RNA and protein levels of PGC-1a, TFAM and NRF1.
PGC-1a commercial antibodies are widely criticised for lacking
specificity. We found the same problem and were not confident in
drawing conclusions from the antibody tried. Measuring PGC1
RNA levels by real-time PCR also proved difficult, we were not
able to quantify expression of PGC1 in any of our lymphoblast
samples due to low signal. This finding is supported by another
study which found levels of PGC1 expression in lymphoblast cells
to be very low [43].
However when we measured expression levels of mitochon-
drial biogenesis proteins that are activated downstream of PGC1
to drive mitochondrial DNA transcription (TFAM) and nuclear
mitochondrial protein transcription (NRF1) we found a signif-
icant increase in the protein level (by western blotting) of NRF1
in the PV group (Figure 7), however mtTFAM was not
significantly upregulated. The RNA expression levels were not
significantly changed for either of these genes but did follow the
same trend.
Discussion
In this study we identified variations in OXPHOS capacity
between ADOA patients who maintain or lose vision. We show
that lymphoblasts derived from ADOA patients with normal vision
maintain ATP synthesis rates that are above those of poor vision
patients. The relative preservation of mitochondrial ATP produc-
tion in normal vision ADOA patient lymphoblasts compared to
poor vision patients may occur via compensation of OXPHOS
function. We found higher cell respiration rates together with
increased distal OXPHOS complex activity and protein expres-
sion. This signature of increased mitochondrial function in normal
vision patients has not been observed before and may point toward
potential compensatory pathways associated with preserved vision.
The decrease in OXPHOS capacity in poor vision patients
supports other published reports. These other studies were in
patients with clinical signs of optic atrophy and vision impairment
[18,26,43], including one study in which 75% of patients had
visual acuity worse than 6/18 [26]. In these studies, patients
presenting with clinical symptoms showed a reduced ATP content
and ATP synthesis across different OPA1 mutations including the
c.2709-2711delTTAG in exon 27 [26], the R445H mutation [43]
and in five other OPA1 mutations [18]. In patients with multi-
system disorders associated with OPA1 mutations (ADOA+), the
degree of energetic impairment was significantly more pronounced
than in patients with ‘typical’ OPA1 mutations [44,45]. This
precedent exists with the previously recognized LHON+ syndrome
in which OXHOS studies demonstrated more severe biochemical
defects than associated with the ‘typical’ LHON complex I
mtDNA gene mutations [46]. When considered in context with
other reports [25,44] our data indicate that OXPHOS capacity
may be a key pathway altered in ADOA patients with vision loss,
in whom increasing dysfunction leads to involvement of other
vulnerable neuronal populations resulting in more complex
phenotypes.
We initially hypothesised that alterations in oxidative phos-
phorylation function may contribute to the decreased ATP
synthesis observed in our poor vision patients. In these patients
we did not detect significant differences in the OXPHOS enzyme
complex activities when compared to controls. This supports a
previous study that examined OXPHOS activities in six clinically
affected (i.e. poor vision) ADOA patient lymphoblast cell lines.
Mayorov et al (2008) found no difference in complexes III, IV and
citrate synthase between their ADOA patients and controls with
only a slight decrease in the complex I activity. Further
polarographic analysis of respiration in isolated mitochondria also
showed no decrease compared to controls [47], which was also
observed in another study by Spinazzi et al [48], with both these
studies agreeing with our finding of normal intact cell respiration
in our poor vision patient cells. These studies did not include ATP
production assays. Thus our findings of no changes in OXPHOS
rates between our PV and C patients support Mayorov’s data.
Figure 3. Decreased OPA1 protein levels in ADOA patient cells.
A) Representative Western blots of OPA1 protein in patient and control
cells. B) Quantification relative to actin shows a decrease in total OPA1
content in both normal vision and poor vision ADOA compared to
controls. *** p,0.001.
doi:10.1371/journal.pone.0021347.g003
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acuity adds the novel finding of increased cell respiration, OXPHOS
capacity and relatively preserved mitochondrial ATP production
in patients who maintain normal visual acuity. An increased
mitochondrial respiratory capacity (increased OXPHOS and
respiration) may be a response of the cell to maintain ATP
synthesis, and the failure to respond to this (in the PV group) may
result in a decline in ATP synthesis.
Figure 4. Reduced ATP production and endogenous respiration in poor vision ADOA patients. The rate of mitochondrial ATP synthesis
was determined in cells treated with 50 ug/ml digitonin. ATP synthesis driven by A) complex I (glutamate plus malate) or B) complex II (succinate plus
rotenone) substrates was determined. This shows a significant decrease in complex I and II driven ATP production in poor vision, but not normal
vision ADOA compared to controls. C) An example trace showing respiration of intact cells on endogenous substrates (routine), leak (oligomycin
inhibited), maximum electron transport capacity (CCCP titration) and residual oxygen consumption (ROX). D) Cell respiration in vivo at intracellular,
non-saturating ADP levels showed normal vision ADOA cells have a higher routine respiration rate.
doi:10.1371/journal.pone.0021347.g004
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tion differences by western blotting of mitochondrial proteins with
antibodies directed against complex IV nuclear- and mtDNA-
encoded subunits as well as key subunits of oxidative phosphor-
ylation proteins. In support of the oxidative phosphorylation
enzymology data, both nuclear- and mtDNA-encoded complex IV
subunits were significantly increased in the normal vision patients.
This may point to key changes in mitochondrial biogenesis or gene
regulation that allow for upregulation of certain OXPHOS
complexes, and this upregulation may mediate protection against
decline in visual acuity in our NV patients. We found that NRF1
protein levels were modestly increased in the PV group, with a
non-significant trend for higher TFAM protein levels, and similar
non-significant trends for higher NRF1 and TFAM transcript
levels measured by real-time PCR. These results suggest that the
NV patients are able to increase some aspects of OXPHOS
function independently of the PGC1 axis. We speculate that the
PV patients’ cells may be less able to compensate in the same way,
but are attempting to upregulate the PGC1 pathway.
A limitation of this study is the sample size of our patient groups.
We limited the number of families involved in this study to
minimise the number of OPA1 mutations included. The majority
of patients chosen were from the largest ADOA pedigrees with a
wider range of acuities among siblings. Furthermore not all of
these extensively studied pedigrees shared the same range of VA,
one pedigree with 100% penetrance had an overall average poorer
visual acuity than other pedigrees, as discussed previously [7]. We
sampled patients at the extremities of VA to allow the most
significant biochemical differences to be detected. Within this
study there were two younger patients included in the NV group.
Figure 5. Oxidative phosphorylation complex activities are increased in normal vision patients. Lymphoblast mitochondria were used to
determine the specific activity of OXPHOS enzymes. A) cytochrome c reduction at 550 for complex II+III linked assay, B) cytochrome c reduction at
550 for complex III, C) oxidation of ferrocytochrome c at 550 nm for complex IV, D) NADH oxidation at 340 nm for complex I and E) DCIP reduction at
600 nm for complex II. The data was normalised to the citrate synthase activity of each mitochondrial sample. Data are average +/2 SEM. (P) poor
vision (n=8), (N) normal vision (n=7), (C) controls (n=21) for 3 independent experiments. There was a significant increase in the complex II+III
activity in normal vision ADOA, with trends of increased complex III and IV when compared to poor vision ADOA.
doi:10.1371/journal.pone.0021347.g005
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early as 3–5 years of age, and in a recent study 80% of individuals
were symptomatic before the age of 10 years, with the average age
of onset being 7 years [27].
The relationship between OPA1 haploinsufficiency and mito-
chondrial structure and function, and neuronal viability has been
extensively demonstrated in Caenrhabditis elegans, drosophila and
rodent models. Mutations of OPA1 orthologues resulted in
impaired oxidative phosphorylation [20,49] together with a
marked increase in susceptibility to oxidative stress [20], increased
reactive oxygen species production and mitochondrial fragmenta-
tion [23]. These OPA1 mutations contributed to decreases in the
number of RGCs [19] impaired visual function [21,22] and lower
visual evoked potential measurements [50]. These were not
associated with any mtDNA mutations or COX deficiencies
[24]. These models mimic the human disease, with progressive
Figure 6. Western blot analysis of complex IV and porin expression in ADOA cell lysates show increases in normal vision ADOA
patients. Total cellular protein was loaded onto a 12% acrylamide gel, transferred and probed with a suite of antibodies (Table S3). A,B) There was a
significant increase in CxIV subunit II and IV content as well as C) porin in normal vision ADOA compared to poor vision ADOA and controls. However
there was no change in expression of other OXPHOS enzymes including Complex I, Complex II, Complex III and ATP synthase (data not shown). D) A
representative blot. Data is average +/2 SEM. (P) poor vision (n=8), (N) normal vision (n=7), (C) controls (n=21) for 3 independent experiments.
doi:10.1371/journal.pone.0021347.g006
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haploinsufficiency may lead to increased oxidative stress, mito-
chondrial dysfunction and eventual loss of RGCs.
Our studies suggest that genetic modifiers influence the course
of RGC loss in OPA1-linked ADOA. The mitochondrial
haplogroup has been excluded as a disease modifier in ADOA
[32,33]. Our pedigrees also argue against mtDNA haplogroup
having a strong influence on phenotype, since we show strong
discordance within sibships that share haplotypes.
Identifying the genetic variants that contribute to the OXPHOS
compensation we observed in patients with normal vision may
permit new methods for predicting individuals most at risk of
losing vision, and also identify novel therapeutic targets for
preserving RGCs in primary optic neuropathies including
glaucoma, in which mitochondrial dysfunction may also have a
role in pathogenesis [51,52].
Materials and Methods
Patient grouping and selection
For this study we recruited ADOA patients from the six largest
of 17 pedigrees within our population cohort of 158 subjects [7].
These individuals had one or more of six different OPA1
mutations including: exon 27 2708delTTAG, exon 9&11
937AG.TA and 1126A.G, exon 19 1298G.A, intron 9 985-
1g.a and exon 2 112C.A and deletion of a copy of the entire
OPA1 gene (Figure 1B). Across the six pedigrees there were a total
of 119 patients carrying OPA1 mutations. These pedigrees have
been extensively described elsewhere [7].
To determine whether there is an association between visual
acuity and mitochondrial function, we ranked patients according
to their best-corrected visual acuity (BCVA) and then derived
lymphoblast lines from the ADOA patients with the upper and
lower percentiles of visual acuity. (Figure 1A, Table S1, and
Table 1). This generated two groups of ADOA patients that were
used for comparison - the ‘‘normal’’ vision group (NV)’’ with
normal optic disc appearance and visual acuity greater than 6/9 in
the best eye (n=7) and the ‘‘poor vision’’ group (PV)’’ with visual
acuity less than 6/36 (n=8) in the presence of clear optic disc
pallor. Patients with visual acuity in the mid-range (less than 6/9
but better than 6/36) were not included for mitochondrial studies.
For further comparison, we employed lymphoblast lines from
nineteen subjects from the CEPH (Centre d’Etude du Polymor-
phisme Humain, Utah residents with ancestry from northern and
western Europe) HAPMAP population at the Corriell cell
repository [53], which has been used as a reference European
American population [54] in both functional and genomic studies
[55,56,57]. We also included one non-mutation carrying ADOA
family member who was a genetically unrelated marriage partner.
Clinical assessment and ethics statement
ADOA subjects were recruited from different clinical centres
across Australia. The study conformed to the tenets of the Helsinki
Declaration, and informed written consent was obtained from all
participants prior to being included in the study. The protocol for
the research project was approved by the local Ethics Committee
(Royal Victorian Eye and Ear Hospital, Melbourne, Australia) and
the work was undertaken conforming to the provisions of the
Figure 7. Gene and protein expression levels of mitochondrial biogenesis markers. Total cellular protein was loaded onto a 12%
acrylamide gel, transferred and probed with antibodies against NRF1, mtTFAM and b-actin (Table S3). Gene expression was measured by RT-PCR
using probes for NRF1, mtTFAM and b-actin A) There was a significant increase in NRF1 protein expression content in poor vision ADOA compared to
normal vision ADOA and controls. However there was no change in gene expression of C) NRF1 or gene expression of B) mtTFAM or D) protein
expression of mtTFAM. Data is average +/2 SEM. (P) poor vision (n=8), (N) normal vision (n=7), (C) controls (n=21) for 3 independent experiments.
doi:10.1371/journal.pone.0021347.g007
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subjects gave written informed consent. A 10 ml blood sample was
collected from each patient. Participants were examined using
Snellen acuity charts or logMAR charts for BCVA. When the
measurement was recorded in Snellen acuity, the reading was then
converted to the logMAR equivalent for analysis [58]. The
Farnsworth–Munsell 100 Hue test was used to test colour vision
and visual fields were assessed with Humphrey 24-2 SITA
automated perimetry (Humphrey Field Analyser II, Zeiss-Hum-
phrey, Dublin, CA, USA). Stereoscopic optic disc photography
was performed with a Nidek Stereo Fundus 3-Dx/F camera
(Nidek, Gamagori, Japan). Analysis of the optic cup area, vertical
cup-to-disc ratio and neuro-retinal rim area was performed
stereoscopically using custom software (StereoDx) with a Zscreen
(StereoGraphics, Beverly Hills, CA, USA) [59,60].
EBV transformation of B-lymphocytes and lymphoblast
culture
B-cell lines were generated using established techniques [35].
Briefly, blood stored in EDTA blood tubes (Greiner Bio-one) for
up to 3 days at room temperature was successfully used to isolate
lymphocytes and transform with Epstein-Barre Virus. Trans-
formed lymphoblasts were maintained in RPMI (2 mg/ml
glucose, Gibco) with 15% heat-inactivated fetal calf serum (56uC
for 30 minutes, Gibco) and penicillin/streptomycin (Sigma).
Culture flasks were kept on an angle in a humidified 37uC/5%
CO2 incubator. Lymphoblast lines were archived at passages 3 to
4 and used for experiments up to passage 25.
Transmission Electron Microscopy (TEM)
Lymphoblasts were fixed using 2.5% glutaraldehyde, stained
and embedded for TEM using standard protocols. Sections were
viewed under a Phillips CM10 electron microscope and images
captured on film. Images were scanned and adjusted to a pre-
calibrated scale bar and mitochondrial, nuclear and cytoplasmic
area and mitochondrial lengths and widths measured using ImageJ
software [61].
Mitochondrial isolation and OXPHOS enzymology
Intact mitochondria were isolated from lymphoblasts following
gentle lysis with digitonin as previously described (Trounce et al
1996). We are able to obtain high levels of mitochondrial purity
using this isolation technique, determined by western blotting
using mitochondrial, endoplasmic reticulum and lysosomal specific
markers (data not shown). Aliquots of mitochondrial fractions were
stored at 280uC so that OXPHOS assays could be performed on
complete groups to minimize inter-assay variation. Prior to
OXPHOS assays, mitochondria were disrupted by sonication.
Isolates were diluted to 1 mg/ml in isolation buffer on ice, and
disrupted on an ice slurry using 4 pulses over 3 seconds at power
1.5 (,4 watts)(Misonix Microson Ultrasonic homogeniser -
Misonix, USA, fitted with a 3.2 mm microprobe). OXPHOS
complexes I, II, III, II+III and IV, and citrate synthase assays were
performed as previously described [62] except that a single beam
spectrophotometer was used (Cary 3000 spectrophotometer,
Varian, USA).
Mitochondrial DNA analysis
Probes to span the entire human mtDNA genome were
produced using 5 PCR fragments as previously described
[63,64] and are listed in Table S2. A probe representing a
fragment of the nuclear 18sRNA gene was produced by PCR as
described previously [65].
DNA was extracted from cells using the Qiagen DNAse
extraction kit according to the manufacturer’s protocol. 5 mgo f
DNA was cut using BamHI (NEB, according to the manufactur-
er’s protocols), which has a single restriction site in most human
mtDNAs. The restricted DNA samples, along with molecular
weight marker (500 ng lambda phage DNA digested with HindIII),
were electrophoresed on a 0.6% (w/v) agarose (Scientifix) gel
+10 mg/ml ethidium bromide in TBE buffer overnight at 40 V.
Following transfer to Hybond N+ nylon membrane (Amersham)
and probing with 32P-labelled hybridization probes, hybridizing
bands were visualized on a phosphoimager screen. Images were
quantified using ImageJ software [61].None of the ADOA patients
in this study linked in with any of the 60 Leber’s Hereditary Optic
Neuropathy (LHON) matrilineal pedigrees in Australia.
Western Blot
Total cell or mitochondrial protein lysates (20–50 mg) were
electrophoresed on SDS-PAGE reducing gels (8–14% acrylamide
depending on separation required, Biorad). Proteins were
transferred to Hybond N+ nylon membranes (Amersham, GE
Healthcare), membranes blocked with 5% (w/v) skim milk in PBS
for 1 hour at room temperature, and washed in 0.05% tween-20/
PBS three times. Membranes were then probed with primary
antibodies in 5% BSA/PBS overnight (Table S3) at 4uC, washed
in 0.05% tween-20/PBS three times and probed with appropriate
horse radish peroxidase conjugated secondary antibodies. Primary
and secondary antibodies used in this study are listed in Table S3.
Following development with ECL detection reagents (Amersham,
GE Healthcare), membranes were exposed to autoradiography
film (Amersham, GE Healthcare). Autoradiography films were
scanned to .tiff files using Arcsoft Photos Studio 5 (Arcsoft Inc,
2003) and bands were quantified using Image J software [61].
Mitochondrial ATP synthesis in cultured lymphoblasts
The amount of cellular ATP was determined by using a
luciferin/luciferase assay as previously described [66,67,68] with
some modifications. The measurements of mitochondrial ATP
synthesis were performed in cells grown in RPMI with 2 mg/ml
glucose and 15% heat inactivated fetal calf serum. Cells were
Table 1. ADOA patient summary.
Group OPA1 mutations* VA range Age Gender
Poor Vision - PV 16A, 26B, 36C, 16D, 16F 6/36-count fingers 25–60 3M 5F
Normal Vision - NV 36C, 16D, 36E, 16F 6/5–6/9 10–66 4M 3F
Control - C non mutation controls Normal vision, unknown 6–63 13M 8F
*A=2Arg38 STOP (c112C.T), B=exon10 985-1G.C, C=exon27 4bpdel 2708delTTAG, D=1798G-T Glu600STOP exon1, E=entire OPA1 del, F=exon9 937A-G & 938T-A
& exon11 1126A-G.
doi:10.1371/journal.pone.0021347.t001
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6 cells/ml) in buffer A (10 mmol/L KCl,
25 mmol/L Tris-HCl, 2 mmol/L EDTA, 0.1% bovine serum
albumin, 10 mmol/L potassium phosphate, 0.1 mmol/L MgCl2
(pH 7.4)), kept for 15 minutes at room temperature, and then
incubated with 50 mg/mL digitonin for 1 minute. After centrifu-
gation, the cell pellet was resuspended in the same volume of
buffer A and aliquots used to measure ATP synthesis. Measure-
ments were performed at 30uC in a 96-well luminescent
platereader (Fluorostar Optima, BMG instruments) in white-
walled, white-based 96-well plates. 50 ml aliquots of digitonin
permeabilised cells were incubated for 5 minutes with 50 mlo f
256 diluted FLAAM luciferase/luciferin reagent (Sigma) either
with 5 mmol/L malate plus 5 mmol/L glutamate (measuring ATP
production via complex I) or with 10 mmol/L succinate plus
2 mg/mL rotenone (measuring ATP production via complex II).
Parallel samples were also included with 10 mg/ml oligomycin to
inhibit ATP synthase. Luminescence was monitored for 5 minutes
prior to the addition of 0.2 mM ADP, then luminescence was
monitored for 30 minutes. The rate of ATP synthesis was linear
for over 30 minutes, was dependant on cell density and substrate
concentration, and the luminescence signal was eliminated by
either the addition of oligomycin (ATPase inhibitor) or by not
providing substrates (data not shown).
Endogenous respiration in intact lymphoblasts
Cell respiration in vivo is regulated according to intracellular,
non-saturating ADP levels. We used the Oxygraph-2 k high
resolution respirometer (Oroboros Instruments, Innsbruck Austria)
because of the superior resolution of slow oxygen consumption
rate transitions the machine can measure compared with
conventional oxygen electrodes [69]. Following saturation of
RPMI growth media (RPMI with 2 mg/ml glucose and 15% heat
inactivated fetal calf serum) at ambient oxygen for 30 min at 30uC,
cells were added to the chamber at 7610
5 cells/ml and respiration
measured (R). Non-phosphorylating leak state of respiration (L),
mainly caused by compensation of the proton leak after inhibition
of ATP synthase, was then induced by the addition of oligomycin
(2 mg/ml). Uncoupled maximal respiration (UC) was then
measured by addition of CCCP (Carbonyl cyanide 3-chlorophe-
nylhydrazone, 5 mM). The respiratory control ratio (R-L/UC),
which reflects the state of activation of cellular respiration
according to routine endogenous ATP demand, was derived from
these values [70,71]. Oxygen consumption was calculated using
DataGraph software (Oroboros Instruments).
Gene expression by real-time PCR
For each cell line 3 independent cultures of each cell line grown
under identical culturing conditions in RPMI (2 mg/ml glucose,
15% HI-FCS, PSF). Isolated cells were used for RNA extraction
using Qiagen RNA isolation kit (Qiagen, Hilden, Germany). cDNA
was generated from equal amounts of total RNA per sample using
Applied Biosystems High Capacity RNA-to-cDNA kit (Applied
Biosystems). Equal volumes of cDNA were transferred into the real-
time PCR reaction. All Taqman Gene Expression Assay (Applied
Biosystems) probes used spanned an exon junction to prevent
amplification of genomic DNA. Commercially available probes
included NRF1 (Hs00192316_m1: FAM dye), mtTFAM
(Hs01082775_m1: FAM dye), PGC1a (Hs01016719_m1: FAM
dye) and b-actin as a housekeeper reference gene (Hs99999903_m1:
VIC dye, primer limited), all which were provided as 206solutions.
Standard curves were generated for all probes by a 1:10 serial
dilution of a control cDNA sample. Reaction efficiencies were
.95% for all probes except PGC1, with R-squared values
exceeding 0.97. Real-time PCR reactions were run in duplex
reactions with the gene of interest probe and the housekeeping
probe present in each reaction vial. Each 15 ml reaction consisted
of: 7.5 mlo f2 6Taqman Mastermix (Applied Biosystems), 0.75 ml
of 206 gene of FAM labelled ‘‘gene of interest’’ probe (NRF1,
PGC1a or mtTFAM), 0.75 mlo f2 0 6 gene of VIC labelled,
primer limited ‘‘housekeeper’’ probe (b-actin), 1 ml of diluted
cDNA and water to 15 ml. Negative controls included water only
and reverse transcription reactions without RNA present. The
real-time reactions were run using a RotorGene Q instrument
(Qiagen, Hilden, Germany) and the following cycles: 1 cycle of
50uC for 2 minutes then 95uC for 10 minutes followed by 40
cycles of 95uC for 15 seconds then 60uC for 60 seconds. Data
acquisition for both probes occurred during the 60uC cycle. The
PCR products were verified by gel electrophoresis. To avoid
inter-assay variability all samples analysed were performed with
the same cDNA dilution, with an internal control sample present
in each assay. To further verify the accuracy of real-time PCR
reactions the ‘‘gene of interest’’ and b-actin probes were amplified
in the same tubes, as well as each probe individually. The intra-
assay and intra-well variation was low for all probes. CT values
for each sample were analysed by the Rotor-gene 6000 software
(Version 1.7, Corbitt Research) and the delta-delta analysis
algorithm and the threshold values determined from each probe’s
standard curves. Expression levels were measured in triplicate
and expressed as relative quantification of the gene of interest to
b-actin.
Statistical analysis
All data are presented as mean 6 SEM. Statistical analyses
were performed using a commercially available software package.
(SPSS H v 15.00, SPSS Inc., Chicago, IL). Two-tailed Student’s t-
test with assumed equal variance and two way ANOVA with
Tuckey’s post-test was used for comparison between groups with
alpha of 0.05.
Supporting Information
Figure S1 Mitochondrial DNA content in ADOA patient
cells. A) Southern blot of BamH1 digest of total cell DNA probed
with 5 overlapping mtDNA probes, while the lower panel shows
the 18S rDNA probe labelling for nuclear gene quantification. B)
There was no significant change in mtDNA levels between normal
vision ADOA (NV), poor vision ADOA (PV) or controls (C), nor
were there large-scale deletions indicated by lower molecular
weight mtDNA bands.
(TIF)
Figure S2 Transmission Electron Microscopy images of
ADOA and control cells. A) EM micrographs of PV ADOA,
NV ADOA and controls. Bar scale: 1 mm. B) Mitochondrial area
per cell was quantified and divided by the cytoplasmic area. There
was no significant difference in mitochondrial area per area of
cytoplasm between any of the groups. Per group .10 cells were
scored for total mitochondrial, nuclear and cytoplasmic volume.
C) Mitochondrial area was plotted against frequency (% total
mitochondria) to display the size distribution of mitochondria per
cell. Per group .150 mitochondria were measured.
(TIF)
Table S1 Table of patient characteristics. Patients were
categorised into the following groups: 1) ‘‘normal vision ADOA’’
where visual acuity was greater than 6/9, 2) ‘‘poor vision ADOA’’
where visual acuity was less than 6/36, or 3) non mutation
carrying family member controls or from the well described
pedigrees from the HAPMAP population at the Corriell cell
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characteristics including OPA1 mutation and visual acuity for
both the left and right eye are shown (CF=count fingers).
(DOC)
Table S2 Primer pairs used to produce PCR probes
spanning entire human mtDNA genome. Primers were
designed for the six generated PCR fragments to cover the entire
mtDNA genome. Numbers in brackets indicates position align-
ment to human mtDNA genome.
(DOC)
Table S3 Antibodies used for western blotting. A list of
commercially available antibodies that were used for western
blotting.
(DOC)
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